Torres-Quesada 2022 MitoFit Kinase

From Bioblast
Jump to navigation Jump to search


MitoFit Preprints         MitoFit Preprints        
Gnaiger 2019 MitoFit Preprints
       
Gnaiger MitoFit Preprints 2020.4
        MitoFit DOI Data Center         MitoPedia: Preprints


Torres-Quesada 2022 MitoFit Kinase


Publications in the MiPMap
Torres-Quesada Omar, Strich Sophie, Stefan Eduard (2022) Kinase perturbations redirect mitochondrial function. MitoFit Prep 2022.11. https://doi.org/10.26124/mitofit:2022-0011

»

MitoFit pdf

Kinase perturbations redirect mitochondrial function

Torres-Quesada Omar, Strich Sophie, Stefan Eduard (2022-04-11) MitoFit Prep

Abstract: Protein kinases take the center stage in numerous signaling pathways by phosphorylating compartmentalized protein substrates for controlling cell proliferation, cell cycle and metabolism. Kinase dysfunctions have been linked to numerous human diseases such as cancer. This has led to the development of kinase inhibitors which aim to target oncogenic kinase activities. The specificity of the cancer blockers depends on the range of targeted kinases. Therefore, the question arises of how cell-type-specific off-target effects impair the specificities of cancer drugs. Blockade of kinase activities has been shown to converge on the energetic organelle, the mitochondria. In this review, we highlight examples of selected major kinases which impact mitochondrial signaling. Further, we discuss pharmacological strategies to target kinase activities which are linked to cancer progression and redirecting mitochondrial function. Finally, we propose that cell-based recordings of mitochondrial bioenergetic states might predict off-target or identify specific on-target effects of kinase inhibitors.

Keywords: Kinases, signaling, mitochondria, kinase inhibitors, cancer, drug off-target effects Bioblast editor: Doerrier C O2k-Network Lab: AT Innsbruck Oroboros


ORCID: ORCID.png Torres-Quesada Omar, ORCID.png Stefan Eduard


Labels: MiParea: Pharmacology;toxicology  Pathology: Cancer 

Organism: Human 





MitoKIN, Bioblast 2022